Trial Profile
A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Advanced/Metastatic Solid Tumors and B-cell Non-Hodgkins Lymphoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 05 Oct 2020
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Urelumab (Primary)
- Indications Carcinoma; Diffuse large B cell lymphoma; Follicular lymphoma; Head and neck cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 10 Sep 2020 Status changed from completed to discontinued.
- 08 May 2019 This trial has been discontinued in Spain, according to European Clinical Trials Database.
- 29 Apr 2019 Status changed from active, no longer recruiting to completed.